G1 sees stock bump on big data readout

Research Triangle Park-based G1 Therapeutics (Nasdaq: GTHX) saw its stock up more than 8 percent Monday afternoon, trading north of $27 per share following a big data readout. The company received good news from a Phase 2a trial of trilaciclib, its drug for patients undergoing chemotherapy treatment for small cell lung cancer.  "The data from this trial showed clear evidence that trilaciclib preserved bone marrow and immune system function from the damaging effects of chemotherapy," said Chief…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news